Filing Overview
This Form 8-K was filed on November 3, 2022, by Vallon Pharmaceuticals, Inc., not GRI Bio, Inc. The report covers the quarter ended September 30, 2022 and references a press release providing financial results and a business update. The referenced press release was furnished as Exhibit 99.1 but its contents are not included in the provided filing text.
Financial Results and Liquidity
The filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, margins, cash and equivalents, debt, liquidity, or other financial metrics. These details may be contained in Exhibit 99.1, which is not included here.
Material Changes Versus Prior Period
The filing does not provide sufficient information to identify material changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing states that the company provided a business update, but does not include the underlying commentary, guidance, outlook, risks, contingencies, or unusual items. The report is furnished rather than filed for purposes of Section 18 liability and is not incorporated by reference into other SEC filings.
Investor Verification Items
- Verify the correct issuer: the filing identifies Vallon Pharmaceuticals, Inc. and trading symbol VLON, while the request metadata identifies GRI Bio, Inc.
- Obtain and review Exhibit 99.1 for the September 30, 2022 financial results and business update.
- Verify cash balances, operating cash burn, liquidity runway, debt, and financing requirements.
- Review any clinical, regulatory, development, or corporate updates included in the referenced press release.